RainDance Joins French HTS Screening Consortium | GenomeWeb
NEW YORK (GenomeWeb News) – Microfluidics company RainDance Technologies said today that it has joined a French consortium to develop a microfluidic system for use in quantitative high-throughput screening of potential drug compounds.
 
In addition to the Lexington-Mass.-based company, the dScreen Consortium includes the drug-maker Sanofi-Aventis and the Institute for Science and Supramolecular Engineering at Louis Pasteur University of Strasbourg. The consortium was founded with assistance from the Alsace BioValley cluster.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.